Partow Kebriaei on Monitoring Patients for Cytokine Release Syndrome

Video

Partow Kebriaei, MD, from MD Anderson Cancer Center, discusses how nurses can monitor patients for cytokine release syndrome.

Partow Kebriaei, MD, of MD Anderson Cancer Center, discusses what to be aware of when treating patients who have undergone CAR T-cell therapies.

Cytokine release syndrome (CRS) and other neurotoxicities often occur within the first 2 weeks after infusion of CAR T-cell therapy. During this time, symptoms such as fever may not seem alarming but can be indications of CRS. It is important to carefully monitor these patients through vitals, daily weight, and mental status. Close observation during the first weeks after the CAR T-cell therapy is necessary to catch CRS in these patients.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Recent Videos
Photo of a man wearing a suit with a bowtie in front of an Oncology Nursing News backdrop
Photo of a woman with blond hair wearing a white and black blazer
Photo of a woman with brown hair and bangs, surrounded by a blue border